CAMBRIDGE, Mass., May 13 /PRNewswire-FirstCall/ -- Transkaryotic
Therapies, Inc. (Nasdaq: TKTX) today announced that the company will present
at Banc of America's 2004 Health Care Conference being held May 19-21 in Las
Vegas, Nevada. Michael J. Astrue, President and Chief Executive Officer will
present an overview of TKT's business activities at 11:20 a.m. Pacific Time on
Thursday, May 20, 2004. A live audio webcast of this presentation will be
available at http://www.tktx.com on TKT's Investor Information website under the
Events category. A replay will be available until June 3, 2004.
About TKT
Transkaryotic Therapies, Inc. is a biopharmaceutical company primarily
focused on researching, developing and commercializing treatments for rare
diseases caused by protein deficiencies. Within this focus, the company
markets Replagal(TM), an enzyme replacement therapy for Fabry disease, and is
developing treatments for Hunter syndrome and Gaucher disease. Outside its
focus on rare diseases, TKT intends to commercialize Dynepo(TM), its Gene-
Activated(R) erythropoietin product for anemia related to kidney disease, in
the European Union. TKT was founded in 1988 and is headquartered in Cambridge,
Massachusetts, with additional operations in Europe, Canada and Latin America.
Additional information about TKT is available on the company's website at
http://www.tktx.com.
Gene-Activated(R) is a registered trademark and Replagal(TM) is a
trademark of Transkaryotic Therapies, Inc. Dynepo(TM) is a trademark of
Aventis Pharmaceuticals, Inc.
Contact:
Daniella M. Lutz
Corporate Communications Specialist
(617) 349-0205
SOURCE Transkaryotic Therapies, Inc.
 back to top
Related links:
http://www.tktx.com
Company News On-Call:
http://www.prnewswire.com/comp/120657.html
CONTACT:
Daniella M. Lutz of Transkaryotic Therapies,
Inc., Corporate Communications Specialist, +1-617-349-0205
|
